Femara Tablet, Film Coated
Product Images NDC 0078-0249

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Femara (NDC 0078-0249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Femara Drawing (Femara 01)

Chemical structure of letrozole, the active ingredient in Femara 2.5 mg tablets. The diagram shows the molecular arrangement including nitrogen and carbon atoms with cyano groups at specific positions on the aromatic rings.*

FDA Label Image

Figure 1: Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Femara 02)

A Kaplan-Meier survival curve graph comparing treatment outcomes for Letrozole and Tamoxifen over 72 months. The solid line represents Letrozole and the dashed line represents Tamoxifen. The graph includes patient statistics such as number of patients, events, and censored data for each treatment group, as well as monthly patient counts at risk.*

FDA Label Image

Femara Fig2 (Femara 03)

A Kaplan-Meier curve graph showing progression-free survival over time in months, comparing Femara 2.5 mg (solid line) and tamoxifen 20 mg (dashed line). The y-axis represents the proportion progression-free, and the x-axis shows time in months up to 60.*

FDA Label Image

Femara Fig 3 (Femara 04)

A survival curve graph showing the proportion of patients alive over time in months. The solid line represents 'letrozole 1st' and the dashed line represents 'tamoxifen 1st.' The y-axis is labeled 'Alive,' ranging from 0.0 to 1.0, and the x-axis is labeled 'Months,' spanning 0 to 60 months. A horizontal dashed line indicates the 50% survival level.*

FDA Label Image

Femara Fig 4 (Femara 05)

A line graph showing time to progression in days on the x-axis and proportion remaining on the y-axis, depicting three treatment groups: Femara 0.5 mg, Femara 2.5 mg, and MA. The graph illustrates changes in progression over approximately 1000 days for each dosage group.*

FDA Label Image

Femara Fig 5 (Femara 06)

A Kaplan-Meier survival curve chart showing time to progression in days. It compares three treatment groups: Femara 0.5 mg, Femara 2.5 mg, and AG, with different line styles representing each group. The vertical axis measures progression probability from 0 to 1, and the horizontal axis measures time up to 1000 days.*

FDA Label Image

Principal Display Panel – Package Label – 2.5 mg Tablets (Femara 07)

Label for Femara (letrozole) tablets, 2.5 mg strength, film-coated oral tablets. The label includes the product NDC 0078-0249-15, the Novartis Pharmaceuticals Corporation logo, and indicates a package size of 30 tablets. Additional label text contains dosage and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.